home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

95.31 -2.32 (-2.38%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2

...

14 15 16 17 18 19 20 21 22

...

27 28 Next >

Incyte Skin Disease Drug Meets Primary Goal In Late-Stage Study In Children ↗

July 12, 2023

Incyte Corporation (NASDAQ: INCY) released topline results from its Phase 3 TRuE-AD3 study evaluating the safety and efficacy of ruxolitinib cream (Opzelura) in children with

Via Benzinga

Incyte Announces Positive Topline Results from Phase 3 Trial Evaluating Ruxolitinib Cream (Opzelura®) in Children with Atopic Dermatitis

July 11, 2023

From Incyte

Via Business Wire

Syndax Pharmaceuticals Set for Potential Breakthrough with Revumenib: Analyst Calls It 'Potentially Best-In-Class' In Competitive Landscape ↗

July 11, 2023

Guggenheim Partners initiated coverage on Syndax Pharmaceuticals Inc (NASDAQ: SNDX) with a BUY rating and a

Via Benzinga

Incyte to Report Second Quarter Financial Results

July 11, 2023

From Incyte

Via Business Wire

Incyte Stock Crumbles As Seasonality Hammers Away At First-Quarter Sales ↗

May 02, 2023

Incyte's biggest moneymaker, Jakafi, missed first-quarter forecasts.

Via Investor's Business Daily

Why Incyte Shares Are Falling Today ↗

May 02, 2023

Incyte Corporation's (NASDAQ: INCY) shares are plunging today after the

Via Benzinga

Earnings Outlook For Incyte ↗

May 01, 2023

Via Benzinga

Ominous Death Cross Forms On Incyte's Chart ↗

April 13, 2023

Via Benzinga

2 Low-Priced Stocks That Could Make You Richer ↗

June 26, 2023

These two low-priced healthcare stocks could skyrocket within the next 12 months.

Via The Motley Fool

How Biotech Stocks Are Revolutionizing Healthcare Investment Opportunities ↗

June 17, 2023

The field of biotechnology has become a driving force behind groundbreaking medical advancements, offering investors the opportunity to benefit from these innovations. Here are 10 healthcare innovators...

Via Talk Markets

Data from Across Incyte’s Oncology Portfolio Accepted for Presentation at the 2023 ASCO Annual Meeting and EHA2023 Hybrid Congress

May 25, 2023

From Incyte

Via Business Wire

Incyte to Present at Upcoming Investor Conferences

May 23, 2023

From Incyte

Via Business Wire

What 13 Analyst Ratings Have To Say About Incyte ↗

March 28, 2023

Via Benzinga

Incyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership Role

May 08, 2023

From Incyte

Via Business Wire

Market Rally Finishes Strong; Regional Banks, Fed Rate Hike, Jobs Report, Apple In Focus: Weekly Review ↗

May 05, 2023

The major indexes retreated for most of the week on banking fears,

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023 ↗

May 04, 2023

Via Benzinga

Incyte Reports 2023 First Quarter Financial Results and Provides Updates on Key Clinical Programs

May 02, 2023

From Incyte

Via Business Wire

Incyte Announces Results from SCRATCH-AD Trial Demonstrating Substantial and Rapid Itch Reduction in Patients with Mild-Moderate Atopic Dermatitis Treated with Opzelura® (ruxolitinib) Cream

May 01, 2023

From Incyte

Via Business Wire

What To Expect When Incyte Reports Q1 Earnings In Almost Two Weeks ↗

April 21, 2023

Incyte Corporation (NASDAQ: INCY) will report Q1 FY23 results on May 2. Investor focus remains on the Opzelura launch, which has faced some hiccups over the first 18 months of launch and began to gain...

Via Benzinga

Incyte Announces European Commission Approval of Opzelura® (ruxolitinib) Cream for the Treatment of Non-Segmental Vitiligo with Facial Involvement in Adults and Adolescents

April 20, 2023

From Incyte

Via Business Wire

7 Biotech Stocks That Could Cure Your Portfolio Woes ↗

April 19, 2023

If you want to revitalize your portfolio with some exciting opportunities, these biotech stocks to buy might fit the bill.

Via InvestorPlace

Incyte to Present at Upcoming Investor Conferences

April 18, 2023

From Incyte

Via Business Wire

MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)

April 16, 2023

From Incyte and MorphoSys U.S. Inc.

Via Business Wire

The Unexpected Way The Texas Abortion Ruling Could Destroy Biotech ↗

April 14, 2023

One executive called this the most "damaging" decision in five decades.

Via Investor's Business Daily

Incyte to Report First Quarter Financial Results

April 11, 2023

From Incyte

Via Business Wire

S&P 500 Stocks: Micron, Charles Schwab Among Top Performers Monday ↗

April 10, 2023

Micron and Charles Schwab were among the top performers.

Via Investor's Business Daily

Incyte Faces Increased Competition From Emerging JAK Inhibitors, RBC Capital Lowers Price Target ↗

April 10, 2023

Shares of Incyte Corporation (NASDAQ: INCY) recovered last week, after having been under pressure on setbacks to its LIMBER Program.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 10, 2023 ↗

April 10, 2023

Via Benzinga

Valero Energy To Rally 32%? Here Are 10 Other Analyst Forecasts For Monday ↗

April 10, 2023

Credit Suisse boosted the price target for The Boeing Company (NYSE: BA) from $200 to $220. Credit Suisse analyst Scott Deuschle maintained a Neutral rating on the stock. Boeing shares fell 0.4% to...

Via Benzinga

Incyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)

March 27, 2023

From Incyte

Via Business Wire

< Previous 1 2

...

14 15 16 17 18 19 20 21 22

...

27 28 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com